Xencor Inc. (XNCR)
XNCR trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1326732/000132673226000015/0001326732-26-000015-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | XNCR on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2013 |
| SEC CIK | 0001326732 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $125.6M |
| Net income | -$91.9M |
| Operating income | -$177.5M |
| Net margin | -73.2% |
| Operating margin | -141.4% |
| Revenue growth | +13.7% |
| Cash | $54.1M |
| Total assets | $875.5M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 21.2× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-04 |
| Cash and burn | $59.6M cash; operating cash flow -$43.1M a quarter. | Report 2026-09-30 |
| Shares outstanding | 75,039,689 (2026-10-30); 71,410,469 a year earlier; 60,875,198 three years earlier. | Cover page 2026-10-30 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-02-25 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | KPMG LLP, San Diego, California, United States; changed auditors 2 times in 24 months | 8-K 4.01 2025-03-13 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $3.8M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $116.5M | $39.4M | $2.6M | $59.6M | $95.1M | $200.5M | 10-Q 2026-11-04 |
| Q2 2026 2026-06-30 | $51.2M | -$21.7M | -$55.7M | $44.7M | $104.9M | $105.0M | 10-Q 2026-08-05 |
| Q1 2026 2026-03-31 | $4.5M | -$128.9M | -$67.6M | $14.2M | $108.5M | $97.4M | 10-Q 2026-05-06 |
| Q4 2025 2025-12-31 | $28.2M | -$6.7M | -$51.7M | $54.1M | $119.7M | $125.6M | 10-K 2026-02-25 |
| Q3 2025 2025-09-30 | $21.0M | -$6.0M | -$30.8M | $28.3M | $133.1M | $150.1M | 10-Q 2026-11-04 |
| Q2 2025 2025-06-30 | $43.6M | -$30.8M | -$36.4M | $44.4M | $145.0M | $146.9M | 10-Q 2026-08-05 |
| Q1 2025 2025-03-31 | $32.7M | -$48.4M | -$16.2M | $39.7M | $154.4M | $127.2M | 10-Q 2026-05-06 |
| Q4 2024 2024-12-31 | $52.8M | -$45.6M | -$49.8M | $40.9M | $163.6M | $110.5M | 10-K 2026-02-25 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3ASR | 2026-02-25 |
| Latest annual report | 10-K | 2026-02-25 |
| Latest quarterly / interim | 10-Q | 2026-11-04 |
| Latest current report | 8-K | 2026-11-04 |
| Latest proxy | DEFA14A | 2026-04-27 |
Source: SEC EDGAR submissions feed, 903 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +3.7% |
| 1 month | +57.7% |
| 3 months | +61.3% |
| Year to date | +142.3% |
| 1 year | +165.1% |
| From 52-week high | -7.2% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ZLAB | Zai Lab Limited | $23.47 | -4.59% | $2.6B |
| MBX | MBX Biosciences Inc. | $53.12 | -5.04% | $2.6B |
| HCM | HUTCHMED (China) Limited | $14.73 | -1.14% | $2.6B |
| VCRE | Vicore Pharma Holding AB | $10.16 | -1.93% | $2.9B |
| RCUS | Arcus Biosciences Inc. | $16.86 | -3.27% | $2.4B |
| IDYA | IDEAYA Biosciences Inc. | $30.36 | -4.62% | $2.9B |
| TLX | Telix Pharmaceuticals Limited | $8.92 | -3.36% | $3.0B |
| NAMS | NewAmsterdam Pharma Company N.V. | $19.46 | -3.38% | $2.3B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier